Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma

NCT00509379 is registered in ClinicalTrials.gov with Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie as lead sponsor.

NCT NCT00509379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00509379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Non-randomized Study to Assess Safety, Toxicity and Clinical Activity of the Association of Bortezomib(VELCADE)With Rituximab in Relapsed/Refractory Indolent Non Follicular and Mantle-cell Non-Hodgkin Lymphoma
Lead sponsor
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2006
Completion date
January 31, 2011
Enrollment
48 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin lymphoma